查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1787988

全球抗蛇毒血清市场预测（截至 2032 年），按类型、品种、分销管道、最终用户和地区划分

Snake Antivenom Market Forecasts to 2032 - Global Analysis By Type (Polyvalent Antivenom and Monovalent Antivenom), Species (Elapids, Viperids, Colubrids and Other Snake Species), Distribution Channel, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球抗蛇毒血清市场预计在 2025 年达到 3.8402 亿美元，到 2032 年将达到 6.2886 亿美元，预测期内的复合年增长率为 7.3%。

抗蛇毒血清是用于治疗毒蛇咬伤的生物衍生性药物。它们含有透过少量非致命剂量的毒液使宿主动物（通常是马或羊）免疫而产生的抗体。这些抗体可以中和毒液中的毒素，防止组织和重要器官进一步损害。这些抗体在降低蛇毒中毒的死亡率和併发症发挥重要作用。

根据世界卫生组织 (WHO) 统计，全球整体每年约有 270 万人被蛇咬伤，导致 81,000 至 138,000 人死亡。

蛇咬伤发生率高

蛇咬伤的高发生率仍然是一个突出因素，据估计每年报告的蛇咬伤病例高达270万例。持续存在的发病率和死亡率风险，尤其是在热带和亚热带地区，迫使医疗机构和製造商必须确保抗蛇毒血清的供应。高风险地区人口的成长和气候变迁导致蛇咬伤事件激增，刺激了全球对有效抗蛇毒血清的需求。因此，公共卫生机构越来越重视意识提升、资源配置以及获得救命治疗的机会，这为市场成长提供了巨大的动力。

製造和分销成本高

抗蛇毒血清的生产是一个复杂且资源密集的过程，涉及动物免疫、提取和纯化，所有这些都需要专门的基础设施和专业知识。这些因素增加了产品成本，并对蛇咬伤频繁的中低收入者的负担能力产生了负面影响。此外，一些国家薄弱的报销政策和缺乏价格监管，加剧了药物的可及性挑战，并限制了抗蛇毒血清治疗的普及，尤其是在弱势群体中。

改进物流和数位工具

供应链优化、数位追踪和库存管理的进步，正在增强抗蛇毒血清向偏远高风险地区的及时配送。数位平台有助于即时监控存量基准，从而快速应对当地短缺情况，并提高整体配送效率。此外，远端医疗和医疗资讯系统的实施有助于培训医疗专业人员，加强事件报告，并快速传播治疗通讯协定，最终改善有效治疗的可近性，并扩大市场。

监管障碍和核准延迟

抗蛇毒血清的核准流程通常冗长且各国不一致，导致新产品或改良产品的上市严重延误。这种监管复杂性扼杀了创新，并限制了更安全、更有效的抗蛇毒血清的引入，尤其是在医疗资源匮乏的地区。此外，标准碎片化和协调不力增加了成本，并使全球分销工作更加复杂。随着科学进步，监管调整的延迟也可能限制下一代解决方案的快速部署，这对相关人员构成持续挑战。

COVID-19的影响：

新冠疫情为抗蛇毒血清市场带来了严峻挑战。供应链中断、旅游限制导致的就诊人数减少以及医疗体系内部工作重点的转变，导致疫情高峰期抗蛇毒血清需求低于预期。儘管治疗延误和限制导致部分地区蛇咬伤死亡率上升，但全球市场的销售和产量仍暂时下降。随着疫情情势好转，市场正努力恢復分销，以满足疫情后预期的需求復苏。

预测期内，多效价抗蛇毒血清市场预计将占最大份额

多效价蛇毒血清细分多效价预计将在预测期内占据最大市场占有率，这得益于其在蛇类种群分布区域具有广泛的疗效和效用，因为它能够同时中和多种蛇毒。急诊护理中多价抗蛇毒血清的应用日益增多，以及寻求多功能治疗方案的临床医生的认可，正在增强该细分市场的实力。此外，持续的技术进步和政府对抗蛇毒血清生产日益增长的支持，预计将增强多效价抗蛇毒血清在全球市场的主导地位。

预计预测期内诊所部门的复合年增长率最高

预计诊所细分市场将在预测期内实现最高成长率，这得益于蛇咬伤管理专科诊所的不断增多，尤其是在蛇咬伤高发的农村和服务匮乏地区。诊所提供快速介入和常规抗蛇毒血清，同时减轻了大型医院的负担。此外，政府旨在提高农村地区医疗和临床能力的支持措施进一步提升了成长前景，使诊所成为提高治疗覆盖率和扩大市场规模的重要因素。

占比最大的地区：

预计亚太地区将在预测期内占据最大市场占有率，这主要由于抗蛇毒血清的负担过重，尤其是在印度和东南亚等国家。亚太地区患者人数众多，加上政府和非政府部门为提高公众意识、预防和获取抗蛇毒血清的管道而采取的强有力倡议，推动了该地区强劲的需求。此外，本地製造商的投资不断增加以及医疗基础设施的改善，也支持了该地区在全球市场的主导地位。

复合年增长率最高的地区：

预计亚太地区在预测期内将呈现最高的复合年增长率，这得益于该地区持续的医疗发展、日益增长的蛇咬治疗意识以及在抗蛇毒血清研发和分销方面的大量投资。扩大农村和服务欠缺地区的医疗保健服务，以及努力缩小治疗差距，将在这一预期成长中发挥关键作用。此外，政府对国内製造业的大力支持和简化的监管法规预计将进一步推动该地区的成长。

免费客製化

此报告的订阅者可以使用以下免费自订选项之一：

  • 公司简介
    • 全面分析其他市场参与者（最多 3 家公司）
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球抗蛇毒血清市场（按类型）

  • 多效价蛇毒血清
  • 单价抗毒素

6. 全球抗蛇毒血清市场（依类型）

  • 眼镜蛇
  • 毒蛇
  • 游蛇
  • 其他的

7. 全球抗蛇毒血清市场（依分销管道）

  • 直接竞标（政府采购）
  • 医院药房
  • 零售药局

8. 全球抗蛇毒血清市场（依最终用户）

  • 医院
  • 诊所
  • 军事和偏远设施
  • 非政府组织和卫生使命

9. 全球抗蛇毒血清市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十章：主要发展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章：公司简介

  • BTG International Inc.
  • CSL Limited
  • Bharat Serums and Vaccines Ltd.
  • Instituto Clodomiro Picado（ICP）
  • Serum Institute of India（SII）
  • Inimmune
  • Pfizer, Inc.
  • Merck & Co., Inc.
  • Haffkine Bio-Pharmaceutical Corporation Ltd.
  • Sanofi Genzyme
  • Zydus
  • Daewoong
  • MicroPharm Limited
  • Rare Disease Therapeutics Inc.
  • South African Vaccine Producers（Pty）Ltd.
  • Laboratorios Silanes
Product Code: SMRC30253

According to Stratistics MRC, the Global Snake Antivenom Market is accounted for $384.02 million in 2025 and is expected to reach $628.86 million by 2032 growing at a CAGR of 7.3% during the forecast period. Snake antivenom is a biologically derived therapeutic used to treat venomous snakebites. It contains antibodies developed by immunizing host animals, typically horses or sheep, with small, non-lethal doses of venom. These antibodies neutralize toxins present in the snake venom, preventing further damage to tissues and vital organs. They play a critical role in reducing mortality and complications from envenomation.

According to the World Health Organization (WHO), an estimated 2.7 million cases of snake envenoming occur globally each year, resulting in 81,000 to 138,000 deaths.

Market Dynamics:

Driver:

High incidence of snakebites

The high incidence of snakebites remains a prominent driver, with an estimated 2.7 million cases of snake envenomation reported annually. The persistent risk of morbidity and mortality, especially across tropical and subtropical regions, is compelling healthcare authorities and manufacturers to ensure robust availability of antivenom. A surge in snakebite incidents driven by expanding human populations into high-risk areas and changing climate patterns has expedited global demand for effective antidotes. Consequently, public health institutions are placing increased focus on awareness, resource allocation, and access to life-saving treatments, providing notable impetus to market growth.

Restraint:

High production and distribution costs

Manufacturing antivenom is a complex and resource-intensive process, involving immunization of animals, extraction, and purification, all of which require specialized infrastructure and expertise. These factors contribute to elevated product costs, which adversely affect affordability in low- and middle-income regions where snakebites are frequent. Additionally, inadequate reimbursement policies and a lack of pricing regulation in several countries exacerbate access challenges, thereby limiting the reach of antivenom treatments, especially among vulnerable populations.

Opportunity:

Improving logistics and digital tools

Advances in supply chain optimization, coupled with digital tracking and inventory management, are enhancing the timely distribution of antivenom to remote, high-risk areas. Digital platforms facilitate real-time monitoring of stock levels, enabling swift response to local shortages and improving overall delivery efficiency. Furthermore, the adoption of telemedicine and health information systems supports training for healthcare professionals, bolsters incident reporting, and ensures that treatment protocols are rapidly disseminated, ultimately improving access to effective care and market expansion.

Threat:

Regulatory barriers and approval delays

The antivenom approval process is often prolonged and inconsistent across countries, leading to substantial delays in bringing new or improved products to market. Such regulatory complexities hinder innovation and limit the introduction of safer, more effective antivenoms, particularly in underserved regions. Moreover, fragmented standards and limited harmonization increase costs and complicate global distribution efforts. The slow adaptation of regulations amid evolving scientific advancements may also restrict rapid deployment of next-generation solutions, presenting a continuing challenge for stakeholders.

Covid-19 Impact:

The Covid-19 pandemic imposed significant challenges on the snake antivenom market. Disruptions in supply chains, reduction in healthcare facility visits due to movement restrictions, and shifting priorities within health systems resulted in lower-than-expected demand for antivenom during the peak periods of the pandemic. Although some regions saw an increase in snakebite-related mortality due to delayed or restricted care, the overall global market experienced a temporary decline in sales and production. As pandemic conditions have improved, efforts are underway to restore distribution and address the post-pandemic resurgence in demand.

The polyvalent antivenom segment is expected to be the largest during the forecast period

The polyvalent antivenom segment is expected to account for the largest market share during the forecast period, attributed to the capacity of polyvalent antivenoms to neutralize toxins from multiple snake species simultaneously, providing broad-spectrum efficacy and greater utility in areas with diverse snake populations. Their increased adoption in emergency medical scenarios and favorability among clinicians seeking versatile treatment options reinforce segment strength. Furthermore, ongoing technological advancements and heightened governmental support for antivenom production are anticipated to bolster the dominance of polyvalent antivenoms in the global market landscape.

The clinics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the clinics segment is predicted to witness the highest growth rate, driven by the growing establishment of specialized clinics dedicated to snakebite management, particularly in rural and underserved regions where snakebites are most prevalent. Clinics offer swift intervention and routine access to antivenom while alleviating patient load from major hospitals. Additionally, supportive government initiatives aimed at rural healthcare and capacity-building in clinical settings further amplify growth prospects, making clinics an essential driver for improvement in treatment coverage and market expansion.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to the region's disproportionately high burden of snake envenomation, especially in countries such as India and Southeast Asian nations. Asia Pacific's substantial patient population, coupled with strong governmental and non-governmental initiatives to enhance awareness, prevention, and access to antivenom, drives robust demand. Additionally, the increased investments by local manufacturers and improvements in healthcare infrastructure further support the region's commanding share in the global market.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, fueled by the region's continuous healthcare development, rising awareness of snakebite treatment, and significant investments in antivenom research and distribution. Expansion of healthcare delivery to rural and underserved areas, coupled with efforts to reduce treatment gaps, plays a critical role in this anticipated growth. Moreover, strong governmental backing for domestic manufacturing and regulatory streamlining is expected to further propel growth in this region.

Key players in the market

Some of the key players in Snake Antivenom Market include BTG International Inc., CSL Limited, Bharat Serums and Vaccines Ltd., Instituto Clodomiro Picado (ICP), Serum Institute of India (SII), Inimmune, Pfizer, Inc., Merck & Co., Inc., Haffkine Bio-Pharmaceutical Corporation Ltd., Sanofi Genzyme, Zydus, Daewoong, MicroPharm Limited, Rare Disease Therapeutics Inc., South African Vaccine Producers (Pty) Ltd., and Laboratorios Silanes.

Key Developments:

In April 2025, CSL has expanded its antivenom product range, focusing on faster-acting formulations and broader species coverage. This enhances treatment in regions such as South Asia, where snakebites remain critical.

In April 2025, BSV collaborated with the Indian Institute of Science (IISc) to produce test batches of region-specific anti-snake venoms in India, aiming for more effective responses to local venom variability not addressed by the standard polyvalent ASVs.

Types Covered:

  • Polyvalent Antivenom
  • Monovalent Antivenom

Species:

  • Elapids
  • Viperids
  • Colubrids
  • Other Snake Species

Distribution Channels Covered:

  • Direct Tender (Government Procurement)
  • Hospital Pharmacies
  • Retail Pharmacies

End Users Covered:

  • Hospitals
  • Clinics
  • Military & Remote Field Facilities
  • NGOs & Health Missions

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Snake Antivenom Market, By Type

  • 5.1 Introduction
  • 5.2 Polyvalent Antivenom
  • 5.3 Monovalent Antivenom

6 Global Snake Antivenom Market, By Species

  • 6.1 Introduction
  • 6.2 Elapids
  • 6.3 Viperids
  • 6.4 Colubrids
  • 6.5 Other Snake Species

7 Global Snake Antivenom Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Direct Tender (Government Procurement)
  • 7.3 Hospital Pharmacies
  • 7.4 Retail Pharmacies

8 Global Snake Antivenom Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Clinics
  • 8.4 Military & Remote Field Facilities
  • 8.5 NGOs & Health Missions

9 Global Snake Antivenom Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 BTG International Inc.
  • 11.2 CSL Limited
  • 11.3 Bharat Serums and Vaccines Ltd.
  • 11.4 Instituto Clodomiro Picado (ICP)
  • 11.5 Serum Institute of India (SII)
  • 11.6 Inimmune
  • 11.7 Pfizer, Inc.
  • 11.8 Merck & Co., Inc.
  • 11.9 Haffkine Bio-Pharmaceutical Corporation Ltd.
  • 11.10 Sanofi Genzyme
  • 11.11 Zydus
  • 11.12 Daewoong
  • 11.13 MicroPharm Limited
  • 11.14 Rare Disease Therapeutics Inc.
  • 11.15 South African Vaccine Producers (Pty) Ltd.
  • 11.16 Laboratorios Silanes

List of Tables

  • Table 1 Global Snake Antivenom Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Snake Antivenom Market Outlook, By Type (2024-2032) ($MN)
  • Table 3 Global Snake Antivenom Market Outlook, By Polyvalent Antivenom (2024-2032) ($MN)
  • Table 4 Global Snake Antivenom Market Outlook, By Monovalent Antivenom (2024-2032) ($MN)
  • Table 5 Global Snake Antivenom Market Outlook, By Species (2024-2032) ($MN)
  • Table 6 Global Snake Antivenom Market Outlook, By Elapids (2024-2032) ($MN)
  • Table 7 Global Snake Antivenom Market Outlook, By Viperids (2024-2032) ($MN)
  • Table 8 Global Snake Antivenom Market Outlook, By Colubrids (2024-2032) ($MN)
  • Table 9 Global Snake Antivenom Market Outlook, By Other Snake Species (2024-2032) ($MN)
  • Table 10 Global Snake Antivenom Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 11 Global Snake Antivenom Market Outlook, By Direct Tender (Government Procurement) (2024-2032) ($MN)
  • Table 12 Global Snake Antivenom Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 13 Global Snake Antivenom Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 14 Global Snake Antivenom Market Outlook, By End User (2024-2032) ($MN)
  • Table 15 Global Snake Antivenom Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 16 Global Snake Antivenom Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 17 Global Snake Antivenom Market Outlook, By Military & Remote Field Facilities (2024-2032) ($MN)
  • Table 18 Global Snake Antivenom Market Outlook, By NGOs & Health Missions (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.